BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 14, 2011
 |  BioCentury  |  Emerging Company Profile

Edge Therapeutics: Finding Nimo

Edge: Slow, local delivery of nimodipine for brain hemorrhage

Oral generic nimodipine is the only drug approved to prevent delayed complications of brain hemorrhage. However, the calcium channel blocker must be given at suboptimal doses to reduce the risk of decreased blood pressure and heart rate. Edge Therapeutics Inc. believes its locally delivered, sustained-release NimoGel nimodipine will avoid these risks while improving outcomes.

For two weeks following a subarachnoid hemorrhage, patients are susceptible to cerebral vasospasm, which limits blood flow to the brain and can cause ischemic strokes and additional tissue damage. Nimodipine inhibits calcium ion transfer into smooth muscle, thus preventing contraction of smooth vascular muscle in the brain.

However, systemic delivery of nimodipine also affects smooth vascular muscle in the heart, and thus is associated with a decrease in blood pressure and heart rate. For this reason, the...

Read the full 648 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >